Please assess the completion status of the following clinical trial:

Trial Title: Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Continuous health plan eligibility in the pre- and post-index periods~* age ≥40 years at the index date~* Presence of at least 1 claim with an ICD-9-CM code for COPD in any diagnosis field (490.xx, 491.xx, 492.xx, 496.xx) in the pre- and post-index period~* ≥1 exacerbation in the pre-index period (defined as a COPD-related Emergency Room visit or hospitalization)~* ≥1 prescription claim for ipratropium or ipratropium/albuterol combination in the pre-index period~* an index event of at least one pharmacy claim for TIO (tiotropium) combination in the pre-index period during the study period (January 1, 2003 through April 30, 2008)~* ≥2 prescriptions for TIO (including the index prescription) during the post-index period~Exclusion Criteria:~* presence of comorbid conditions (respiratory cancer, cystic fibrosis, fibrosis due to tuberculosis \[TB\], and bronchiectasis, pneumonociosis, pulmonary fibrosis, pulmonary TB, sarcoidosis) during the pre- and post-index periods~* use of FSC in pre-index period~* exacerbation (emergency room visit or hospitalization) within 30 days after the index date

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- COPD patients (Type: None): Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.

Based on this trial design, predict the completion outcome and termination type (if applicable).